Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1958 1
1959 1
1969 1
1972 1
1975 1
1983 1
1988 1
1989 1
2003 1
2004 7
2005 3
2006 5
2007 4
2008 9
2009 8
2010 9
2011 8
2012 11
2013 11
2014 15
2015 20
2016 21
2017 13
2018 12
2019 26
2020 22
2021 29
2022 22
2023 11

Text availability

Article attribute

Article type

Publication date

Search Results

242 results

Results by year

Filters applied: . Clear all
Page 1
KDM5B promotes immune evasion by recruiting SETDB1 to silence retroelements.
Zhang SM, Cai WL, Liu X, Thakral D, Luo J, Chan LH, McGeary MK, Song E, Blenman KRM, Micevic G, Jessel S, Zhang Y, Yin M, Booth CJ, Jilaveanu LB, Damsky W, Sznol M, Kluger HM, Iwasaki A, Bosenberg MW, Yan Q. Zhang SM, et al. Among authors: kluger hm. Nature. 2021 Oct;598(7882):682-687. doi: 10.1038/s41586-021-03994-2. Epub 2021 Oct 20. Nature. 2021. PMID: 34671158 Free PMC article.
Melanoma: Clinical Presentations.
Kibbi N, Kluger H, Choi JN. Kibbi N, et al. Among authors: kluger h. Cancer Treat Res. 2016;167:107-29. doi: 10.1007/978-3-319-22539-5_4. Cancer Treat Res. 2016. PMID: 26601860 Review.
TCR-sequencing in cancer and autoimmunity: barcodes and beyond.
Pauken KE, Lagattuta KA, Lu BY, Lucca LE, Daud AI, Hafler DA, Kluger HM, Raychaudhuri S, Sharpe AH. Pauken KE, et al. Among authors: kluger hm. Trends Immunol. 2022 Mar;43(3):180-194. doi: 10.1016/j.it.2022.01.002. Epub 2022 Jan 25. Trends Immunol. 2022. PMID: 35090787 Free PMC article. Review.
Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma.
Sarnaik AA, Hamid O, Khushalani NI, Lewis KD, Medina T, Kluger HM, Thomas SS, Domingo-Musibay E, Pavlick AC, Whitman ED, Martin-Algarra S, Corrie P, Curti BD, Oláh J, Lutzky J, Weber JS, Larkin JMG, Shi W, Takamura T, Jagasia M, Qin H, Wu X, Chartier C, Graf Finckenstein F, Fardis M, Kirkwood JM, Chesney JA. Sarnaik AA, et al. Among authors: kluger hm. J Clin Oncol. 2021 Aug 20;39(24):2656-2666. doi: 10.1200/JCO.21.00612. Epub 2021 May 12. J Clin Oncol. 2021. PMID: 33979178 Free PMC article.
Analysis of multispectral imaging with the AstroPath platform informs efficacy of PD-1 blockade.
Berry S, Giraldo NA, Green BF, Cottrell TR, Stein JE, Engle EL, Xu H, Ogurtsova A, Roberts C, Wang D, Nguyen P, Zhu Q, Soto-Diaz S, Loyola J, Sander IB, Wong PF, Jessel S, Doyle J, Signer D, Wilton R, Roskes JS, Eminizer M, Park S, Sunshine JC, Jaffee EM, Baras A, De Marzo AM, Topalian SL, Kluger H, Cope L, Lipson EJ, Danilova L, Anders RA, Rimm DL, Pardoll DM, Szalay AS, Taube JM. Berry S, et al. Among authors: kluger h. Science. 2021 Jun 11;372(6547):eaba2609. doi: 10.1126/science.aba2609. Science. 2021. PMID: 34112666 Free PMC article.
Nivolumab plus ipilimumab in advanced melanoma.
Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, Burke MM, Caldwell A, Kronenberg SA, Agunwamba BU, Zhang X, Lowy I, Inzunza HD, Feely W, Horak CE, Hong Q, Korman AJ, Wigginton JM, Gupta A, Sznol M. Wolchok JD, et al. Among authors: kluger h. N Engl J Med. 2013 Jul 11;369(2):122-33. doi: 10.1056/NEJMoa1302369. Epub 2013 Jun 2. N Engl J Med. 2013. PMID: 23724867 Free PMC article. Clinical Trial.
Agonistic CD40 Antibodies in Cancer Treatment.
Djureinovic D, Wang M, Kluger HM. Djureinovic D, et al. Among authors: kluger hm. Cancers (Basel). 2021 Mar 15;13(6):1302. doi: 10.3390/cancers13061302. Cancers (Basel). 2021. PMID: 33804039 Free PMC article. Review.
Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial.
Goldberg SB, Schalper KA, Gettinger SN, Mahajan A, Herbst RS, Chiang AC, Lilenbaum R, Wilson FH, Omay SB, Yu JB, Jilaveanu L, Tran T, Pavlik K, Rowen E, Gerrish H, Komlo A, Gupta R, Wyatt H, Ribeiro M, Kluger Y, Zhou G, Wei W, Chiang VL, Kluger HM. Goldberg SB, et al. Among authors: kluger hm. Lancet Oncol. 2020 May;21(5):655-663. doi: 10.1016/S1470-2045(20)30111-X. Epub 2020 Apr 3. Lancet Oncol. 2020. PMID: 32251621 Free PMC article. Clinical Trial.
242 results